
|Articles|July 1, 2002
Intravitreal triamcinolone for AMD appears promising, but more studies needed
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Intravitreal triamcinolone appears to inhibit the growth of choroidal neovascularization (CNV) and reduce subretinal fluid in the short term, but it needs further evaluation, ac-cording to Mark Gillies, MB, BS, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope Therapeutics releases positive long-term safety results from EXTEND study
2
Avisi Technologies releases positive 12-month data from VITA Trial
3
Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial
4
Selecting Anti-VEGF Therapies in Retinal Vascular Disease Management
5


















































.png)


